Drug makers want Congress to let them keep patents for two decades to fight generic competition

Drug makers are asking Congress for a simple change: extend the clock on patents by a decade, from 20 years to 30. The argument is blunt. Patents are supposed to reward invention by giving inventors a period of exclusive rights, but the clock starts ticking the moment a patent application is filed, and by the time a drug reaches patients, the window is almost closed.

The cost of developing a single new drug now exceeds $2 billion, and the process often takes more than a decade. A patent filed 20 years ago expires before the drug is even approved. That leaves drug makers with a narrow window of exclusivity, and it means the costs of failure — the vast majority of drug candidates never make it to market — are front-loaded into a short stretch of protected time.

The Patent Clock

Patent terms were set in the mid-1990s to harmonize with global standards. Filing a U.S. patent costs tens of thousands of dollars; securing international protection can run over $100,000 over a patent’s life. The math works against the inventor. A patent application filed today might expire before the drug it covers ever reaches patients.

Fewer than one in eight drug candidates reach the market. The Tufts Center for the Study of Drug Development puts drug development costs at more than $2 billion, including failures and capital costs. When a patent expires, prices often fall 30% to 80%.

Generics and the Price Drop

The history is clear. When generics enter after a patent expires, prices often drop 30% to 80%. That is the intended effect of patent expiration. Some proposals tie extensions to price reductions, rewarding companies that lower costs with additional protection. The article frames patents as “time-limited rewards granted in exchange for public disclosure.” That framing is the core of the argument: the public gets the disclosed knowledge, and the inventor gets a limited period of exclusive rights.

The Cost of Failure

The numbers are stark. A patent application filed today might expire before the drug it covers ever reaches patients. The Tufts estimate of $2 billion in development costs includes failures and capital costs. Fewer than one in eight drug candidates reach the market.

The schedule shows the mismatch. A patent expires 20 years after filing, but a drug takes more than a decade to reach patients. The drug maker has spent billions on a candidate that fails, and the patent that covered it is gone before the drug ever launches.

The Public Interest Case

The argument for extension rests on a balance. Patents are meant to reward invention by giving inventors a period of exclusive rights, but those rights come with a public obligation: the inventor discloses the invention, and the public gains access to that knowledge after the patent expires.

The current system cuts that deal short. A patent filed today might expire before the drug it covers ever reaches patients. The drug maker has spent billions on a candidate that fails, and the patent that covered it is gone before the drug ever launches.

The proposal is straightforward: extend the patent term by 10 years, to 30. That would push the expiration date far enough into the future that the patent survives the development process. The drug maker gets a longer window of protection.

The Counting of Costs

The key facts break down the financial picture:

• Developing a single new drug costs well over $2 billion
• Fewer than one in eight drug candidates reach the market
• A U.S. patent costs tens of thousands of dollars to file
• International protection can exceed $100,000 over a patent’s life
• Patent term was set in the mid-1990s to harmonize global standards
• Patent expiration drops prices 30% to 80%
• Tufts Center for the Study of Drug Development: drug development costs exceed $2 billion

The proposal is not about extending the term indefinitely. It is about aligning the clock with reality. The 20-year term was set when the development timeline was shorter, and it no longer matches the actual path from idea to patient.

The Policy Proposal

The proposal comes from a policy position. The position holds that the current system punishes drug makers for the very thing the patent system is supposed to encourage: investment in risky, expensive research. A 10-year extension would give drug makers a fairer shot at recovering their costs while still protecting the public interest.

The argument is simple: the patent system is broken. The clock starts too soon, and the window closes too fast. A 10-year extension fixes that mismatch. The public gets the eventual benefit of a disclosed invention, and the inventor gets a chance to recover the enormous costs of failure.

Where the paper stands

The paper backs neither side and instead backs a patent system that rewards invention without gathering power, with exclusive rights tied to actual development milestones rather than arbitrary filing dates. The paper believes that patents should grant inventors a fair return on their risks and investments, but the current system punishes drug makers for the very thing the patent system is supposed to encourage: investment in risky, expensive research. The mismatch between the filing date and the approval date is real, and the costs of failure are front-loaded into a short stretch of protected time.

The paper would prefer a system where the clock on a patent does not start until the drug has been developed and approved, so that the inventor’s exclusive rights track the actual development milestones rather than an arbitrary date on a piece of paper. That way, the inventor receives a reward tied to the work done, not to a date that may have nothing to do with the state of the drug.

Source material: “To ease long-term drug pricing pressure, extend patent terms by 10 years now,” the Washington Examiner.

drug pricing · FDA · healthcare reform · patent extension · pharma policy